MYMD Insider Trading Activity and SEC Form 4 Filings
MYMD insider trading summary
No open-market insider purchases or sales of MyMD Pharmaceuticals, Inc. (MYMD) have been reported on SEC Form 4 in the past 12 months.
Latest MYMD insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 24, 2023 | Paul Rivard | Chief Legal Officer | Buy | $167K (150,000 @ $1.11) |
| Aug 17, 2023 | Paul Rivard | Chief Legal Officer | Buy | $28K (25,000 @ $1.12) |
| Dec 8, 2022 | Paul Rivard | EVP of Operations, GC | Buy | $15K (10,000 @ $1.53) |
| Nov 26, 2021 | Joshua Silverman | Director | Buy | $38K (5,000 @ $7.55) |
| Nov 24, 2021 | Joshua Silverman | Director | Buy | $42K (6,734 @ $6.30) |
| Nov 24, 2021 | Joshua Silverman | Director | Buy | $23K (3,266 @ $7.09) |
| Nov 23, 2021 | Paul Rivard | EVP of Operations, GC | Buy | $90K (15,000 @ $6.03) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.